Literature DB >> 19464140

Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver.

D Elias1, D Goéré, G Leroux, C Dromain, S Leboulleux, Th de Baere, M Ducreux, E Baudin.   

Abstract

AIM: The aim of this study was to report the feasibility and early survival results of liver metastases (LM) resection combining cytoreductive surgery and radiofrequency ablation (RFA) during a one-step procedure, in patients presenting more than 15 bilateral LM from well-differentiated endocrine carcinoma. It is an extensive application of the current guidelines.
METHODS: In this retrospective review of a prospectively collected database, we used a combination of hepatectomy to treat large or contiguous LM, and extensively used multiple RFA to treat the remaining LM which were smaller than 2.5 cm. Patients were selected based on a low natural tumor burden slope, and the technical feasibility of treating all the detectable LM.
RESULTS: From January 2002 to May 2007, 16 patients with a median of 23 LM per patient (mean number: 25.7 + or -12; range16-89) underwent this procedure. A mean of 15 + or - 9 LM per patient were surgically removed and a mean of 12 + or - 8 (median of 10) LM per patient were RF ablated. No mortality occurred. Morbidity was observed in 11 patients (69%). The 3-year overall survival and disease-free survival rates were similar to those observed in our preliminary series of 47 hepatectomized patients with a median of 7 LM per patient.
CONCLUSION: This new one-step combined technique allowed us to apply an "upgraded" therapeutic approach to a selection of patients presenting a median of 23 LM per patient and to improve their prognosis, putting it on par with that obtained by conventional hepatectomy.

Entities:  

Mesh:

Year:  2009        PMID: 19464140     DOI: 10.1016/j.ejso.2009.02.017

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  18 in total

Review 1.  When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations.

Authors:  Mickaël Lesurtel; David M Nagorney; Vincenzo Mazzaferro; Robert T Jensen; Graeme J Poston
Journal:  HPB (Oxford)       Date:  2014-03-17       Impact factor: 3.647

Review 2.  Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract.

Authors:  Magaly Zappa; Mohamed Abdel-Rehim; Olivia Hentic; Marie-Pierre Vullierme; Philippe Ruszniewski; Valérie Vilgrain
Journal:  Target Oncol       Date:  2012-05-22       Impact factor: 4.493

3.  Parenchymal-sparing hepatectomies (PSH) for bilobar colorectal liver metastases are associated with a lower morbidity and similar oncological results: a propensity score matching analysis.

Authors:  Riccardo Memeo; Vito de Blasi; René Adam; Diane Goéré; Daniel Azoulay; Ahmet Ayav; Emilie Gregoire; Reza Kianmanesh; Francis Navarro; Antonio Sa Cunha; Patrick Pessaux
Journal:  HPB (Oxford)       Date:  2016-07-05       Impact factor: 3.647

4.  Therapeutic Strategies for Advanced Pancreatic Neuroendocrine Tumors with Segmental Portal Hypertension.

Authors:  F Dumont; Y Goudard; C Caramella; D Goéré; E Baudin; D Elias
Journal:  World J Surg       Date:  2015-08       Impact factor: 3.352

Review 5.  Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies.

Authors:  Skye C Mayo; Joseph M Herman; David Cosgrove; Nik Bhagat; Ihab Kamel; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2012-10-11       Impact factor: 6.113

Review 6.  Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  J Gastroenterol       Date:  2012-08-11       Impact factor: 7.527

7.  Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?

Authors:  Jessica E Maxwell; Scott K Sherman; Thomas M O'Dorisio; Andrew M Bellizzi; James R Howe
Journal:  Surgery       Date:  2015-10-09       Impact factor: 3.982

8.  Radiofrequency ablation resulting in left lobe hypertrophy and improved resectability.

Authors:  R T Jones; J J French; J Scott; D M Manas; R M Charnley
Journal:  Case Rep Gastroenterol       Date:  2011-04-06

9.  Surgical treatment of liver metastases in neuroendocrine neoplasms.

Authors:  Palepu Jagannath; Deepak Chhabra; Shailesh Shrikhande; Rajiv Shah
Journal:  Int J Hepatol       Date:  2012-01-26

10.  Microwave ablation combined with hepatectomy for treatment of neuroendocrine tumor liver metastases.

Authors:  Jin-Zhu Zhang; Shu Li; Wei-Hua Zhu; Da-Fang Zhang
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.